Literature DB >> 7779563

Pentoxifylline. A hydroxyl radical scavenger.

J P Freitas1, P M Filipe.   

Abstract

Pentoxifylline (PTX), a tri-substituted purine and xanthine derivative, has been used for several years to improve microcirculation because of its hemorheological properties. PTX has also antifibrotic and anti-inflammatory effects. We studied the reaction of PTX with the hydroxyl radical and superoxide anion. Hydroxyl radical was generated by a mixture of ascorbic acid, H2O2 and Fe(III)-EDTA. We evaluated the iron-dependent degradation of deoxyribose, mediated by hydroxyl radical, in the presence of different concentrations of PTX (from 0.05 to 3 mM), measuring the degradation products of deoxyribose that react with 2-thiobarbituric acid (TBA). The reaction of PTX with hydroxyl radical occurred with a rate constant of (1.1 +/- 0.2) x 10(10) M-1/s. These results support the properties of PTX as a hydroxyl radical scavenger. Some authors verified that PTX decreases the release of superoxide anion from activated neutrophils. We studied the effect of PTX as a scavenger of superoxide generated in vitro by a hypoxanthine-xanthine oxidase system. PTX was not a superoxide anion scavenger in this system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779563     DOI: 10.1007/BF02790131

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  6 in total

Review 1.  How to characterize a biological antioxidant.

Authors:  B Halliwell
Journal:  Free Radic Res Commun       Date:  1990

Review 2.  Pentoxifylline therapy in dermatology. A review of localized hyperviscosity and its effects on the skin.

Authors:  H Ely
Journal:  Dermatol Clin       Date:  1988-10       Impact factor: 3.478

3.  Gamma and pulse radiolysis study of pentoxifylline, a methylxanthine.

Authors:  C Pasquier; E Franzini; Z Abedinzadeh; M N Kaouadji; J Hakim
Journal:  Int J Radiat Biol       Date:  1991-09       Impact factor: 2.694

4.  Ferrous-salt-promoted damage to deoxyribose and benzoate. The increased effectiveness of hydroxyl-radical scavengers in the presence of EDTA.

Authors:  J M Gutteridge
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

5.  Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline.

Authors:  G W Sullivan; H T Carper; W J Novick; G L Mandell
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

Review 6.  [New aspects of the pharmacology of pentoxifylline].

Authors:  M Lenoble Giovannangeli
Journal:  J Mal Vasc       Date:  1989
  6 in total
  10 in total

1.  Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism.

Authors:  Claudia O Zein; Rocio Lopez; Xiaoming Fu; John P Kirwan; Lisa M Yerian; Arthur J McCullough; Stanley L Hazen; Ariel E Feldstein
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

Review 2.  Therapies in non-alcoholic steatohepatitis (NASH).

Authors:  Abdul M Oseini; Arun J Sanyal
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

3.  Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2.

Authors:  P R Strack; M W Frey; C J Rizzo; B Cordova; H J George; R Meade; S P Ho; J Corman; R Tritch; B D Korant
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

Review 4.  Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease.

Authors:  Alexandra K Leamy; Robert A Egnatchik; Jamey D Young
Journal:  Prog Lipid Res       Date:  2012-11-23       Impact factor: 16.195

5.  Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial.

Authors:  David Wayne Johnson; Carmel Mary Hawley; Brenda Rosser; Elaine Beller; Charles Thompson; Robert G Fassett; Paolo Ferrari; Stephen MacDonald; Eugenie Pedagogos; Alan Cass
Journal:  BMC Nephrol       Date:  2008-08-01       Impact factor: 2.388

6.  Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.

Authors:  Gianni Paulis; Andrea Paulis; Gennaro Romano; Davide Barletta; Andrea Fabiani
Journal:  Res Rep Urol       Date:  2017-07-20

Review 7.  Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review.

Authors:  Gianni Paulis; Gennaro Romano; Luca Paulis; Davide Barletta
Journal:  Adv Urol       Date:  2017-07-04

8.  Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.

Authors:  Gianni Paulis; Giovanni De Giorgio
Journal:  J Med Case Rep       Date:  2022-10-08

9.  A randomized double-blinded placebo-controlled clinical trial on protective effects of pentoxifylline on gentamicin nephrotoxicity in infectious patients.

Authors:  Seyed Ruhollah Mousavinasab; Zohreh Akhoundi-Meybodi; Laleh Mahmoudi; Iman Karimzadeh
Journal:  Clin Exp Nephrol       Date:  2021-04-01       Impact factor: 2.801

10.  Effect of various concentrations of caffeine, pentoxifylline, and kallikrein on hyperactivation of frozen bovine semen.

Authors:  Ibrahim A H Barakat; Mohamed A Danfour; Fatma A M Galewan; Mohamed A Dkhil
Journal:  Biomed Res Int       Date:  2015-04-09       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.